Eris Lifesciences Ltd · NSE:ERIS

Eris Lifesciences — Investor Presentation (June 2023)

35 slides from Eris Lifesciences's investor presentation, Jun 14, 2023

  1. Slide 1: Exchange filing cover letter: Corporate Presentation

    Date: 14 June 2023 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: CORPORATE PRESENTATION Dear Sir/Madam, Pursuant to the requirem

  2. Slide 2: Corporate Presentation June 2023

    CORPORATE PRESENTATION JUNE 2023

  3. Slide 3: Business Highlights

    Business Highlights  Founded in 2007; profitable from the second year of Consolidated Revenue CAGR - 18% in last 2 years Million Indian Rupees operations; pure-play Indian domestic formulations co. 16,851  Youngest among India’s Top-25 domestic branded 13,470 12,119 formulation pharmacos  Chronic

  4. Slide 4: Financial Highlights

    Financial Highlights FY 23 Consolidated Headline Financials Dividend Payout as a % of net profit ₹ mn ₹ mn 26% 16,851 5,367 32% Margin 21% 20% 16% 25% Op Revenue yoy growth EBITDA ₹ mn 3,742 22% Margin FY20 FY21 FY22 FY23 PAT Industry-Leading Margins and Cash Generation  Average Gross Margin (FY18

  5. Slide 5: Significant Diversification of Therapy Mix

    Significant Diversification of Therapy Mix ` in FY 23 Therapy-wise composition of revenue – FY22 Therapy-wise composition of revenue - FY23 100% = INR 1,618 crore 100% = INR 2,342 crore Rest Rest WHC WHC 8% 9% Rank in CNS 4% Diabetes 5% Diabetes CNS 29% CVM - 6 8% 32% 7% Rank in Derma 14% 21% CVM -

  6. Slide 6: Top-20 Power Brands Portfolio Contribute ~70% of Revenue

    Top-20 Power Brands Portfolio Contribute ~ 70% of Revenue Our Top 20 Mother Brands contribute ~ 70% of our revenue Blockbuster additions to power brand portfolio MAT Mar’23 Sales (₹ mn) Market share ` 3,044 6% 1,754 4% • Crossed INR 100+ crore revenue on a MAT basis 1,539 8% (launched in Dec 2019) 1

  7. Slide 7: Distinctive inorganic strategy focused on speedy value creation

    Distinctive inorganic strategy focused on speedy value creation Salient Features of our Inorganic Strategy Key inorganic deals done  Leapfrog our presence in attractive therapies (e.g., Strides - CNS, MJ Biopharm – Insulins, Oaknet/ Glenmark/ Reddy’s - Dermatology, etc.)  Domestic business of  “I

  8. Slide 8: Oaknet business Turned Around in Less Than 12 Months of Acquisition

    Oaknet business Turned Around in Less `Than 12 Months of Acquisition Oaknet Revenue from Operations Oaknet EBIDTA INR Crore INR Crore 61 28% 250 194 189 195 3x 33 Acquired 21 20 Acquired by Eris by Eris FY20A FY21A FY22A FY23A FY20A FY21A FY22A FY23A • Achieved growth of 28% in Oaknet after 3 flat y

  9. Slide 9: Eris Ranked among the Top-10 Fastest Growing Companies in FY23

    Eris Ranked among the Top-10 Fastest Growing ` Companies in FY 23 Eris has outperformed the IPM by 496 bps in FY23 17.8 16.6 15.5 14.3 11.8 11.8 11.5 11.5 11.3 10.7 9.3 IPM INTAS MANKIND TORRENT ERIS LS GSK ABBOTT MACLEODS ALKEM AJANTA ZYDUS Eris continues to rank among the Top-10 companies (by grow

  10. Slide 10: Our Anti-Diabetes Franchise – Robust Growth Across the Board

    Our Anti-Diabetes Franchise – Robust Growth ` Across the Board Revenue from Diabetes Glimisave Mother Brand Zomelis Mother Brand (DPP4) 25% 673 304 104 10% 52% 539 69 278 FY22A FY23A FY22A FY23A FY22A FY23A Tendia Mother Brand (DPP4) Cyblex Mother Brand Gluxit Mother Brand (SGLT2) 81 62 80 59% 18% 1

  11. Slide 11: Our Cardiovascular Franchise – Strong Momentum in Established Brands

    Our Cardiovascular Franchise – Strong Momentum ` in Established Brands Revenue from CVD Therapy* Eritel Mother Brand LN Bloc Mother Brand 468 175 16% 19% 76 15% 404 147 66 FY22A FY23A FY22A FY23A FY22A FY23A Olmin Mother Brand Crevast Mother Brand Atorsave Mother Brand 67 24% 48 62 13% 14% 50 42 59

  12. Slide 12: Our Emerging Therapies – Acquired Critical Mass with Growth Momentum

    Our Emerging Therapies – Acquired Critical` Mass with Growth Momentum Emerging Therapies Revenue* Cosvate Mother Brand Raricap Mother Brand Drolute Brand 75 30% 27 23 607 9% 17% 21 8x 518 69 3 FY22A FY23A FY22A FY23A FY22A FY23A FY22A FY23A • Revenue base of INR 600+ crore • Accounts for 26% of Reve

  13. Slide 13: Strong Position in the ~INR 12,000 Crore Oral Anti-Diabetes Market

    Strong Position in the ~ INR 12,000 Crore Oral Anti-Diabetes Market Eris ranks in Oral Anti-Diabetes therapy Eris has built a full-service presence in Oral Anti-Diabetes therapy with high market ranks in latest generation molecules (DPP4 and By Revenue* Total # Rx** SGLT2 inhibitors) Sulfonylurea 6

  14. Slide 14: High Prescription Ranks among Focus Doctor Specialties

    High Prescription Ranks among Focus Doctor Specialties Eris Prescription Ranking* among Doctor Specialties 5 5 4 DIABETOLOGISTS # CARDIOLOGISTS DERMATOLOGISTS 4 5 7 CONSULTING NEUROLOGISTS GYNECOLOGISTS PHYSICIANS 13 Source: SMSRC MAT Feb 2023│* Rank in Represented Market including Oaknet│# Diabetol

  15. Slide 15: Two Key Pillars of Our Market Engagement

    Two Key Pillars of Our Market Engagement The core focus of our market engagement is to enable clinicians to improve clinical outcomes in patients through timely and precision diagnosis and treatment 1 2 Generation of Patient Care initiatives actionable scientific for precision diagnosis evidence thr

  16. Slide 16: 1a. India-Centric Studies – The India Diabetes Study

    1a. India-Centric Studies – The India Diabetes Study First of its kind nation-wide study Cardiovascular risk in newly diagnosed type 2 diabetes patients in India 5080 Patients │ 1932 Physicians │ 928 Medical centres │ 121 Cities across 27 Indian states 49% 82.5% patients had patients had at least on

  17. Slide 17: 1b. India-Centric – The India Heart Study

    1b. India-Centric – The India Heart Study IHS Methodology IHS Revealed Expert Speak The investigators examined the blood 42% of the participants were White-coat hypertensives get pressure of 18,918 participants with misdiagnosed and were unaware of their misdiagnosed as hypertensive and put the help

  18. Slide 18: 1c. Facilitating Evidence-based Scientific Research and Publications

    1c. Facilitating Evidence-based Scientific Research and Publications Scientific Research and Publications facilitated by Eris in reputed International and Indian Journals Self-blood pressure measurement as compared to Clinical relevance of double-arm blood pressure office blood pressure measurement

  19. Slide 19: 2. Patient Care – Driving Precision Diagnosis and Better Disease Management

    2. Patient Care – Driving Precision Diagnosis and Better Disease Management  Objective - Bring cutting-edge 24,197 1,30,527 healthcare solutions to patients through the involvement of Key Opinion Leaders  State-of-the-art diagnosis at home, followed by treatment options Number of  Helped tens of

  20. Slide 20: Our Manufacturing Infrastructure

    Our Manufacturing Infrastructure Guwahati Site Gujarat Site WHO-GMP manufacturing facility in 70% of revenue (in FY 23) came Guwahati, Assam  Commissioned Greenfield Manufacturing Unit in March 2023 from products manufactured at 100,000 Built-up area (sq. ft) the Guwahati facility  Physical Footpr

  21. Slide 21: Pan-India Sales Presence and Distribution Network

    Pan-India Sales Presence and Distribution Network Stockists Region-wise sales distribution (FY 23) 8 Super Stockists 1 5 74 23 1 45 16% 57 114 44 1 197 53 2 4 39% 28 3 16% 88 131 120 1 34 95 1 249 70 29% 4 97 103 7 2 Central Warehouses 239 1 22 Sales Depots 137 South West North East 2,035 Stockists

  22. Slide 22: Board of Directors

    Board of Directors • Eight-member Board of Directors, comprising of four Amit Bakshi Krishnakumar V Inderjeet Singh Negi Kaushal Shah Executive Directors and four Independent Directors Chairman and Executive Director & Executive Director Executive Director Managing Director Chief Operating Officer •

  23. Slide 23: We will continue our focus on Lifestyle Diseases

    We will continue our focus on Lifestyle Diseases, which will require significant attention and care in the years to come Lifestyle Diseases Prevalence in India Trends in Lifestyle Diseases Abdominal  Significant increase in prevalence of non- Obesity 351 mn communicable diseases (NCDs) in India; Me

  24. Slide 24: Our Key Growth Drivers (FY24 to FY26)

    Our Key Growth Drivers (FY24 to FY26) • Our Top-20 power brands account for 70% of our revenues and have grown at 17% in FY23. 1 Growth in Base 15 out of these brands are ranked among the Top-5 in their respective segments. We have Business • 4 brands with revenues of Rs. 100+ crore each • 6 brands

  25. Slide 25: Our Key Growth Drivers (FY24 to FY26) – Contd..

    Our Key Growth Drivers (FY24 to FY26) – Contd.. Expansion of • We continue to make good progress in expanding our coverage of Specialists and Consulting 3 physician Physicians in line with our expectations coverage • We added ~ 200 Reps to the Eris field-force in FY23 Therapeutic • Strong momentum o

  26. Slide 26: Safe Harbour Statement

    Safe Harbour Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions

  27. Slide 27: Eris Lifesciences Ltd.

    Eris Lifesciences Ltd. CORPORATE OFFICE: Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat 380054 CIN: L24232GJ2007PLC049867 Website : www.eris.co.in IR Contact Kruti Raval kruti@erislifesciences.com 26

  28. Slide 28: Appendix

    Eris APPENDIX

  29. Slide 29: Business Structure and Holdings

    Business Structure and Holdings Eris Lifesciences Limited Promoters 10.02 Aprica Healthcare Limited Earlier known as UTH Healthcare Limited Public 14.86% Eris M. J. Biopharm Private Limited FPI 52.86% Earlier known as Kinedex Healthcare Private Limited DIIs 21.66% Eris Therapeutics Limited Others Er

  30. Slide 30: Financial Summary (1/2)

    Financial Summary (1/2) P&L Summary FY17 FY18 FY19 FY20 FY21 FY22 FY23 Revenue 7,495 8,556 9,822 10,741 12,119 13,470 16,851 Gross Profit 6,449 7,215 8,285 9,025 9,736 10,885 13,328 Gross Profit Margin (%) 86.0% 84.3% 84.4% 84.0% 80.3% 80.8% 79.1% Operating EBITDA 2,691 3,220 3,449 3,684 4,306 4,850

  31. Slide 31: Financial Summary (2/2)

    Financial Summary (2/2) FY17 FY18 FY19 FY20 FY21 FY22 FY23 BS Summary Mar'17 Mar'18 Mar'19 Mar'20 Mar'21 Mar’22 Mar’23 Margin (%) Share Capital 138 138 138 136 136 136 136 Gross Margin 86.0% 84.3% 84.4% 84.0% 80.3% 80.8% 79.1% Reserves 5,534 8,476 11,368 12,828 15,628 18,947 21,819 EBITDA Margin 35.

  32. Slide 32: Key Brands in Oral Diabetes Care

    Key Brands in Oral Diabetes Care Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation fast-growing molecules (DPP4 and SGLT2 inhibitors) Sulfonylurea rank 5 in the ~5,100 cr Glimepiride and combinations market Glimisave MV rank 2 in Glimeperide + Vogli

  33. Slide 33: Key Brands in Cardiovascular and VMN Therapies

    Key Brands in Cardiovascular and VMN Therapies Strong presence in Anti-Hypertensives: the largest segment of Cardiac Care rank 5 in the ~4,400 cr Telmisartan and combinations market Eritel CH rank 5 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in Telmisartan + Cilnidipine market rank 3 in

  34. Slide 34: Key Brands in Derma, CNS and Women's Healthcare Therapies

    Key Brands in Derma, CNS and Women’s Healthcare Therapies Leading brands in Medical Dermatology Cosvate rank 2 in the ≈500 cr Clobetasol and combinations market 15% market share Cosvate-GM rank 1 Clobetasol + Gentamicin + Miconazole market Cosmelite rank 3 in Melasma market Onabet rank 1 in Sertacon

  35. Slide 35: Thank You

    THANK YOU Eris Lifesciences 34

Eris Lifesciences — Investor Presentation (June 2023) on 6ix